99 related articles for article (PubMed ID: 8391513)
1. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.
Richards AM; Crozier IG; Kosoglou T; Rallings M; Espiner EA; Nicholls MG; Yandle TG; Ikram H; Frampton C
Hypertension; 1993 Jul; 22(1):119-26. PubMed ID: 8391513
[TBL] [Abstract][Full Text] [Related]
2. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure.
Richards AM; Crozier IG; Espiner EA; Ikram H; Yandle TG; Kosoglou T; Rallings M; Frampton C
J Cardiovasc Pharmacol; 1992; 20(5):735-41. PubMed ID: 1280735
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic and humoral effects of chronic treatment with the neutral endopeptidase inhibitor SCH 42495 in spontaneously hypertensive rats.
Sala C; Monopoli A; Casati C; Ardeleani G; Ongini E; Zanchetti A; Morganti A
J Cardiovasc Pharmacol; 1994 May; 23(5):703-8. PubMed ID: 7521451
[TBL] [Abstract][Full Text] [Related]
4. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II.
Richards AM; Wittert GA; Crozier IG; Espiner EA; Yandle TG; Ikram H; Frampton C
J Hypertens; 1993 Apr; 11(4):407-16. PubMed ID: 8390508
[TBL] [Abstract][Full Text] [Related]
5. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
[TBL] [Abstract][Full Text] [Related]
6. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension.
Singer DR; Markandu ND; Buckley MG; Miller MA; Sagnella GA; MacGregor GA
Hypertension; 1991 Dec; 18(6):798-804. PubMed ID: 1835959
[TBL] [Abstract][Full Text] [Related]
7. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension.
Richards AM; Crozier IG; Espiner EA; Yandle TG; Nicholls MG
Hypertension; 1993 Aug; 22(2):231-6. PubMed ID: 8340158
[TBL] [Abstract][Full Text] [Related]
8. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
O'Connell JE; Jardine AG; Davidson G; Connell JM
J Hypertens; 1992 Mar; 10(3):271-7. PubMed ID: 1315825
[TBL] [Abstract][Full Text] [Related]
9. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers.
Richards AM; Wittert GA; Espiner EA; Yandle TG; Ikram H; Frampton C
Circ Res; 1992 Dec; 71(6):1501-7. PubMed ID: 1423942
[TBL] [Abstract][Full Text] [Related]
10. Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects.
Richards AM; Wittert G; Espiner EA; Yandle TG; Frampton C; Ikram H
J Hypertens; 1991 Oct; 9(10):955-62. PubMed ID: 1658138
[TBL] [Abstract][Full Text] [Related]
11. Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment.
Lainchbury JG; Richards AM; Nicholls MG; Espiner EA; Yandle TG
J Clin Endocrinol Metab; 1999 Feb; 84(2):723-9. PubMed ID: 10022444
[TBL] [Abstract][Full Text] [Related]
12. Endopeptidase inhibition in angiotensin-induced hypertension. Effect of SCH 39370 in sheep.
Charles CJ; Espiner EA; Richards AM; Sybertz EJ
Hypertension; 1995 Jul; 26(1):89-94. PubMed ID: 7607738
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
Tikkanen T; Tikkanen I; Rockell MD; Allen TJ; Johnston CI; Cooper ME; Burrell LM
Hypertension; 1998 Oct; 32(4):778-85. PubMed ID: 9774379
[TBL] [Abstract][Full Text] [Related]
14. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
Bevan EG; Connell JM; Doyle J; Carmichael HA; Davies DL; Lorimer AR; McInnes GT
J Hypertens; 1992 Jul; 10(7):607-13. PubMed ID: 1321186
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Wallis EJ; Ramsay LE; Hettiarachchi J
Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
[TBL] [Abstract][Full Text] [Related]
17. Atrial natriuretic factor in hypertension: bioactivity at normal plasma levels.
Richards AM; Espiner EA; Ikram H; Yandle TG
Hypertension; 1989 Sep; 14(3):261-8. PubMed ID: 2527819
[TBL] [Abstract][Full Text] [Related]
18. Effects of enalapril maleate on blood pressure, renin-angiotensin-aldosterone system, and peripheral sympathetic activity in essential hypertension.
Cerasola G; Cottone S; D'Ignoto G; Grasso L; Carone MB; Carapelle E; Contorno A
Clin Ther; 1987; 9(4):390-9. PubMed ID: 3038326
[TBL] [Abstract][Full Text] [Related]
19. Effects of the calcium antagonist felodipine on the sympathetic and renin-angiotensin-aldosterone systems in essential hypertension.
Katzman PL; Hulthén UL; Hökfelt B
Acta Med Scand; 1988; 223(2):125-31. PubMed ID: 3279724
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of neutral endopeptidase stimulates renal sodium excretion in patients with chronic renal failure.
Dussaule JC; Michel C; Peraldi MN; Lecomte JM; Gros C; Mignon F; Ardaillou R
Clin Sci (Lond); 1993 Jan; 84(1):31-9. PubMed ID: 8382131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
